Sermorelin vs Tesamorelin: GHRH Analogs Head-to-Head

Sermorelin and tesamorelin are both synthetic GHRH analogs that stimulate pituitary GH release, but they differ in structure, potency, and primary research applications. Sermorelin (GRF 1-29) is the first 29 amino acids of natural GHRH — a straightforward, well-characterised analog used for general GH axis research. Tesamorelin is a 44-amino-acid GHRH analog with a trans-3-hexenoic acid modification that has been specifically researched and FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy. This targeted research history gives tesamorelin unique value for body composition studies in test subjects. For research purposes only.

Structure: Sermorelin = 29 amino acids (GRF 1-29) | Tesamorelin = 44 amino acids + hexenoic acid Half-life: Sermorelin = ~10-20 minutes | Tesamorelin = ~26 minutes Potency: Sermorelin = Moderate | Tesamorelin = Higher Primary research: Sermorelin = General GH stimulation | Tesamorelin = Visceral fat reduction Dose: Sermorelin = 100-300 mcg daily | Tesamorelin = 1-2 mg daily FDA status: Sermorelin = Previously approved (discontinued) | Tesamorelin = Currently approved Visceral fat data: Sermorelin = Limited | Tesamorelin = Extensive clinical data Cost: Sermorelin = Lower | Tesamorelin = Higher (larger doses) Stacking: Sermorelin = Common with secretagogues | Tesamorelin = Often used alone

Choose sermorelin when: The protocol requires a simple, well-characterised GHRH analog for general GH axis research, cost-effectiveness is important, or the study involves stacking with GH secretagogues for synergistic GH release in test subjects. Choose tesamorelin when: The research specifically targets visceral adipose tissue reduction, clinical-grade data and FDA-approval context are important for the study, or the protocol investigates GHRH-mediated body composition changes with published efficacy benchmarks in test subjects. Tesamorelin's unique advantage is its extensive clinical data specifically demonstrating visceral fat reduction — a claim no other GHRH analog can make with the same level of evidence. For research purposes only.